Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.69 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | TERT | O14746 | 3/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | PPARG | P37231 | 3/20 | 0.54 |
| ▸ | PPARD | Q03181 | 3/20 | 0.54 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | FABP4 | P15090 | 2/20 | 0.54 |
| ▸ | GMNN | O75496 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335481 | 1.00 | FAAH (0.69) | FAAHSOAT1CYP1A2CYP2C19KMT2A | |
| SCHEMBL29422232 | 0.90 | SOAT1 (0.50) | FAAHSOAT1CYP1A2CYP2C19KMT2A | |
| SCHEMBL5574516 | 0.90 | SOAT1 (0.50) | FAAHSOAT1CYP1A2CYP2C19KMT2A | |
| SCHEMBL28984571 | 0.90 | SOAT1 (0.50) | FAAHSOAT1CYP1A2CYP2C19KMT2A | |
| SCHEMBL2428089 | 0.90 | SOAT1 (0.50) | FAAHSOAT1CYP1A2CYP2C19KMT2A | |
| SCHEMBL3629441 | 0.83 | FAAH (0.79) | FAAHSOAT1CYP1A2CYP2C19KMT2A | |
| SCHEMBL3629436 | 0.83 | FAAH (0.79) | FAAHSOAT1CYP1A2CYP2C19KMT2A | |
| SCHEMBL5706363 | 0.83 | FAAH (0.79) | FAAHSOAT1CYP1A2CYP2C19KMT2A | |
| SCHEMBL19668673 | 0.83 | TERT (0.61) | FAAHSOAT1CYP1A2CYP2C19KMT2A | |
| SCHEMBL28206503 | 0.83 | TERT (0.61) | FAAHSOAT1CYP1A2CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110223257-A1 | RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | ENZON PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2362728-A1 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM | Enzon Pharmaceuticals, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-2355799-A1 | RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | Enzon Pharmaceuticals, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010057160-A9 | RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | ENZON PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2010057150-A1 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | ENZON PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010057160-A1 | RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | ENZON PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110223257-A1 | RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | FUS, HNRNPUL2, HNRNPDL | FAAH 1534/4885SOAT1 282/4885CYP1A2 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.